Research shows gene therapies can offer cost savings potential of up to $1.8M over five years for patients with certain blood diseases
Arecent analysis by Health Advances looks at two particularly burdensome hematological (or blood) diseases — beta thalassemia andhemophilia A— and finds that potential gene therapies in the pipeline could reduce per patient costs by as much as 41% and 90%, respectively, over five years. Research-based knowledge gained in recent years about the genetic foundation for these diseases has facilitated the pursuit of several promising gene t herapy approaches. (Source: The Catalyst)
Source: The Catalyst - January 15, 2021 Category: Pharmaceuticals Authors: Katie Koziara Tags: Rare Diseases Drug Cost New Era of Medicine The Value Collaborative Source Type: news

Sana Biotechnology aims to raise $150M in IPO
Sana Biotechnology Inc. intends to go public this year, according to a Wednesday filing with the U.S. Securities and Exchange Commission. The preclinical biotech is looking to raise up to $150 million on the Nasdaq under the symbol SANA. The gene therapy company, which was co-founded in July 2018 by former Juno Therapeutics Chief Financial Officer Steve Harr, announced last year it had raised more than $700 million in venture capit al. It has grown from 37 full-time employees in December 2018 to… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - January 13, 2021 Category: American Health Authors: Megan Campbell Source Type: news

Sana Biotechnology aims to raise $150M in IPO
Sana Biotechnology Inc. intends to go public this year, according to a Wednesday filing with the U.S. Securities and Exchange Commission. The preclinical biotech is looking to raise up to $150 million on the Nasdaq under the symbol SANA. The gene therapy company, which was co-founded in July 2018 by former Juno Therapeutics Chief Financial Officer Steve Harr, announced last year it had raised more than $700 million in venture capit al. It has grown from 37 full-time employees in December 2018 to… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 13, 2021 Category: Biotechnology Authors: Megan Campbell Source Type: news

AskBio taps industry vet for C-suite role in wake of Bayer deal
Fresh off of its acquisition by Bayer AG, Research Triangle Park-based Asklepios BioPharmaceutical Inc. has created a new C-suite position and tapped an industry veteran to fill it. Dr. Katherine High has been named president of therapeutics at AskBio and will also serve on its board of directors. She will be responsible for driving the strategic direction and execution of the company’s preclinical and clinical programs. AskBio, a clinical-stage adeno-associated virus (AAV ) gene therapy company,… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 13, 2021 Category: Pharmaceuticals Authors: Cameron Snipes Source Type: news

Bayer-transforms-pharma-business-through-breakthrough-innovation-in-healthcare
Emerging leadership in field of cell and gene therapies / Accelerating breakthrough innovation for patients / Innovation in field of digital health solutions to become key pillar of Bayer’s pharmaceutical business empowering patients with Integrated Care offerings / Promising development portfolio with more than 50 projects in clinical development phases (Source: Bayer Company News)
Source: Bayer Company News - January 13, 2021 Category: Pharmaceuticals Source Type: news

Catalent Agrees to Acquire Dry Powder Inhaler Spray Drying, Capsule...
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today...(PRWeb January 13, 2021)Read the full story at https://www.prweb.com/releases/catalent_agrees_to_acquire_dry_powder_inhaler_spray_drying_capsule_manufacturing_and_packaging_capabilities_from_acorda_therapeutics/prweb17658599.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 13, 2021 Category: Pharmaceuticals Source Type: news

Gene therapy firm Bluebird Bio, with Durham site, to split into two companies
The Massachusetts-based public company with operations in Durham says it plans to spin out its cancer drugs now in development. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 11, 2021 Category: Biotechnology Authors: Don Seiffert Source Type: news

Gene therapy firm Bluebird Bio, with Durham site, to split into two companies
The Massachusetts-based public company with operations in Durham says it plans to spin out its cancer drugs now in development. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - January 11, 2021 Category: American Health Authors: Don Seiffert Source Type: news

What Is Gene Therapy? How Does It Work?
Gene therapy is the process of replacing defective genes with healthy ones, adding new genes to help the body fight or treat disease, or deactivating problem genes. It holds the promise to transform medicine and create options for patients who are living with difficult, and even incurable, diseases. Learn how this innovative therapy works. (Source: FDA Consumer Health Information Updates)
Source: FDA Consumer Health Information Updates - January 11, 2021 Category: Consumer Health News Authors: FDA Source Type: news

California gene therapy firm plans 200-job, $80M operation in Durham
Project Mercury, identified Thursday as a subsidiary of California-based Adverum Biotechnologies (NASDAQ: ADVM), is investing $80 million into a new facility in Durham — a 200-job commitment. Adverum picked Durham over competing sites in both California and Massachusetts, according to the North Carolina Department of Commerce, whose Economic Investments Committee approved the project for $3.3 million in incentives Thursday morning. Adverum, according to what th e company told N.C. Commerce, is… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 10, 2021 Category: Biotechnology Authors: Lauren Ohnesorge Source Type: news

California gene therapy firm plans 200-job, $80M operation in Durham
Project Mercury, identified Thursday as a subsidiary of California-based Adverum Biotechnologies (NASDAQ: ADVM), is investing $80 million into a new facility in Durham — a 200-job commitment. Adverum picked Durham over competing sites in both California and Massachusetts, according to the North Carolina Department of Commerce, whose Economic Investments Committee approved the project for $3.3 million in incentives Thursday morning. Adverum, according to what th e company told N.C. Commerce, is… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 10, 2021 Category: Pharmaceuticals Authors: Lauren Ohnesorge Source Type: news

Gene therapy strategy found effective in mouse model of hereditary disease TSC
(Massachusetts General Hospital) Patients with a genetic disorder called tuberous sclerosis complex have noncancerous tumors growing in numerous organs, and their treatment options are limited. A gene therapy strategy effectively treated mice that express one of the mutated genes that cause the disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 8, 2021 Category: International Medicine & Public Health Source Type: news

Redwood City gene therapy company plans 200-job, $80M manufacturing center in North Carolina
The company is pushing its one-shot-and-done therapy for blinding eye diseases deeper into clinical trials. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - January 7, 2021 Category: Health Management Authors: Lauren Ohnesorge Source Type: news

Gene therapy beats premature-aging syndrome in mice
(Source: ScienceNOW)
Source: ScienceNOW - January 7, 2021 Category: Science Authors: Kaiser, J. Tags: Cell Biology, Genetics, Medicine, Diseases In Depth Source Type: news

Leaps-Bayer-leads-USD-million-Series-B-financing-Senti-Bio-develop-next-generation-therapies-using
Senti Bio’s gene circuit technology platform has the potential to optimize cell and gene therapies across delivery modalities and therapeutic areas / Proceeds to support platform expansion and advance multiple allogeneic CAR-NK cell therapy pipeline candidates for difficult-to-treat cancers, including acute myeloid leukemia and hepatocellular carcinoma (Source: Bayer Company News)
Source: Bayer Company News - January 6, 2021 Category: Pharmaceuticals Source Type: news

The best-performing Austin stocks in 2020
Genprex Inc. (Nasdaq: GNPX), a gene therapy company headquartered in the Texas capital, took the regional title of the year ’s largest increase in share value. Its stock mushroomed by 1,279%. Meanwhile, share value for SolarWinds Corp. (NYSE: SWI) — whose IT management software was hacked and used to gain access to networks at Fortune 500 companies and the U.S. departments of Commerce, Defense Homeland Security and T reasury, among other federal agencies — fell by roughly 16%. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 29, 2020 Category: Pharmaceuticals Authors: Mike Cronin Source Type: news

The best-performing Austin stocks in 2020
Genprex Inc. (Nasdaq: GNPX), a gene therapy company headquartered in the Texas capital, took the regional title of the year ’s largest increase in share value. Its stock mushroomed by 1,279%. Meanwhile, share value for SolarWinds Corp. (NYSE: SWI) — whose IT management software was hacked and used to gain access to networks at Fortune 500 companies and the U.S. departments of Commerce, Defense Homeland Security and T reasury, among other federal agencies — fell by roughly 16%. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 29, 2020 Category: Biotechnology Authors: Mike Cronin Source Type: news

The Petri Dish: Gene therapy trials paused, and an $815M cancer drug sale
The Petri Dish is a roundup of news that may get overlooked amid the influx of health care happenings. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 24, 2020 Category: American Health Authors: Allison DeAngelis Source Type: news

Scientists at Tel Aviv University develop new gene therapy for deafness
(American Friends of Tel Aviv University) A new study from Tel Aviv University (TAU) presents an innovative treatment for deafness, based on the delivery of genetic material into the cells of the inner ear. The genetic material " replaces " the genetic defect and enables the cells to continue functioning normally. They maintain that this novel therapy could lead to a breakthrough in treating children born with various mutations that eventually cause deafness. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 23, 2020 Category: International Medicine & Public Health Source Type: news

Roche ’s faricimab meets primary endpoint and shows strong durability across two global phase III studies for diabetic macular edema, a leading cause of blindness
Basel, 21 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from two identically designed global phase III studies, YOSEMITE and RHINE, evaluating its investigational bispecific antibody, faricimab, in people living with diabetic macular edema (DME). Both studies met their primary endpoint and showed that faricimab given every eight weeks and at personalised dosing intervals of up to 16 weeks demonstrated non-inferior visual acuity gains compared to aflibercept given every eight weeks. Faricimab was generally well-tolerated, with no new safety signals identified. The studies each h...
Source: Roche Media News - December 21, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s faricimab meets primary endpoint and shows strong durability across two global phase III studies for diabetic macular edema, a leading cause of blindness
Basel, 21 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from two identically designed global phase III studies, YOSEMITE and RHINE, evaluating its investigational bispecific antibody, faricimab, in people living with diabetic macular edema (DME). Both studies met their primary endpoint and showed that faricimab given every eight weeks and at personalised dosing intervals of up to 16 weeks demonstrated non-inferior visual acuity gains compared to aflibercept given every eight weeks. Faricimab was generally well-tolerated, with no new safety signals identified. The studies each h...
Source: Roche Investor Update - December 21, 2020 Category: Pharmaceuticals Source Type: news

Taysha Gene Therapies picks Durham for 200-job, $75 million operation
A gene therapy company that recently went public has picked Durham for a new manufacturing operation with hundreds of jobs. Taysha Gene Therapies of Texas has chosen Durham over Dallas for a $75 million capital investment. The company plans on leasing space for a 160,000-square-foot facility — a move that means 201 high-paying jobs. According to the N.C. Department of Commerce, the jobs pay average wages of $119,751. A project brief shows the firm considered a location in its home state of… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 18, 2020 Category: American Health Authors: Lauren Ohnesorge Source Type: news

Research brief: Researchers discover new way to deliver DNA-based therapies for diseases
(University of Minnesota) University of Minnesota Twin Cities researchers in the Department of Chemistry have created a new polymer to deliver DNA and RNA-based therapies for diseases. For the first time in the industry, the researchers were able to see exactly how polymers interact with human cells when delivering medicines into the body. This discovery opens the door for more widespread use of polymers in applications like gene therapy and vaccine development. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - December 18, 2020 Category: Infectious Diseases Source Type: news

Gene therapy company picks North Carolina over Dallas for 200-job, $75 million operation
A locally based gene therapy company that recently went public has picked Durham, North Carolina for a new manufacturing operation with hundreds of jobs. Taysha Gene Therapies has chosen Durham over Dallas for a $75 million capital investment. The company plans on leasing space for a 160,000-square-foot facility – a move that means 201 high-paying jobs. According to the N.C. Department of Commerce, the jobs pay average wages of $119,751. A proj ect brief shows the firm considered a location… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 17, 2020 Category: Biotechnology Authors: Lauren Ohnesorge Source Type: news

Texas gene therapy company picks Durham for 200-job, $75 million operation
A gene therapy company that recently went public has picked Durham for a new manufacturing operation with hundreds of jobs. Taysha Gene Therapies of Texas has chosen Durham over Dallas for a $75 million capital investment. The company plans on leasing space for a 160,000-square-foot facility – a move that means 201 high-paying jobs. According to the N.C. Department of Commerce, the jobs pay average wages of $119,751. A project brief shows the firm considered a location in its home state of… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - December 17, 2020 Category: Health Management Authors: Lauren Ohnesorge Source Type: news

Philadelphia gene therapy firm Passage Bio signs lease deal for lab space in New Jersey
Passage Bio, a Philadelphia company developing gene therapies for rare central nervous system disorders, has entered into a long-term lease for lab space in central New Jersey. The new laboratory, at the Princeton West Innovation Campus in Hopewell, is expected to open in the second quarter of 2021. Passage Bio (NASDAQ: PASG) has leased about 62,000 square feet of lab space at the campus, which is intended to support analytics, process development, quality control and p ilot manufacturing. The lab… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - December 17, 2020 Category: Health Management Authors: John George Source Type: news

FUJIFILM Irvine Scientific Introduces Sterile Express Media Service
The first manufacturing service of its kind delivers tested sterile, non-GMP media designed for feasibility testing before scale-up, to support development of cell and gene therapies  (Source: The Scientist)
Source: The Scientist - December 15, 2020 Category: Science Tags: The Scientist The Marketplace Source Type: news

Lilly Announces Agreement to Acquire Prevail Therapeutics
Acquisition will establish a gene therapy program at Lilly, anchored by Prevail's portfolio of neuroscience assets, and will broaden Lilly's commitment to use novel modalities to attempt to address otherwise fatal genetic forms of neurodegenerative disease... Biopharmaceuticals, Mergers & Acquisitions Eli Lilly, Prevail Therapeutics (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 15, 2020 Category: Pharmaceuticals Source Type: news

Penn vision researchers honored by End Blindness 2020
(University of Pennsylvania) The Outstanding Achievement Prize highlights the contributions of the School of Veterinary Medicine's Gustavo D. Aguirre and the Perelman School of Medicine's Jean Bennett and Albert M. Maguire toward a gene therapy for a form of blindness. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 15, 2020 Category: International Medicine & Public Health Source Type: news

Gene therapy for placental insufficiency moves toward the clinic
(Mary Ann Liebert, Inc./Genetic Engineering News) A new study identified an adenovirus gene therapy vector carrying a VEGF isoform. It can improve uterine blood flow in placental insufficiency. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - December 15, 2020 Category: Biology Source Type: news

The Scientist?'s LabTalk - Episode 4???
The Past, Present, and Future of Gene Therapy: How to Scale-up Successfully (Source: The Scientist)
Source: The Scientist - December 11, 2020 Category: Science Tags: Sponsored Videos Source Type: news

Gene Therapy in One Eye Improves Vision in Both Eyes
It’s not clear why the patients with Leber hereditary optic neuropathy, a mitochondrial disorder that causes blindness, also experienced the modest benefits in their untreated eye. (Source: The Scientist)
Source: The Scientist - December 11, 2020 Category: Science Tags: News & Opinion Source Type: news

Gene Therapy Shows No Long-Term Harm in Animals: Study
FRIDAY, Dec. 11, 2020 -- Results from a long-term study of a gene therapy technique to prevent inherited mitochondrial disease show promise, researchers say. Studies of the technique at Oregon Health& Science University in Portland show no... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 11, 2020 Category: General Medicine Source Type: news

Though Promising, Gene Therapies Face Durability And Reimbursement Headwinds
High upfront costs make it hard for payers to underwrite the risk of full payment for one therapy, let alone the entire range of gene therapies in the pipeline. A combination of installment plans and value-based contracting will likely be the wave of the future for gene therapy reimbursement. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - December 11, 2020 Category: Pharmaceuticals Authors: Joshua Cohen, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & Source Type: news

Massive biotech factory for gene therapy could double in size – and help the Covid fight before that
Mayo Pujols, who started mid-pandemic as CEO of Andelyn Biosciences, the gene therapy manufacturing affiliate of Nationwide Children's Hospital, discusses why its massive Columbus facility could double – and why it might play a role in Covid-19 response even before it opens. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 11, 2020 Category: American Health Authors: Carrie Ghose Source Type: news

Catalent Appoints Nakaya Matsumaru as General Manager of its New...
Catalent, the leading global provider of advanced delivery technologies, development, manufacturing and clinical supply solutions for drugs, biologics, cell and gene therapies, and consumer health...(PRWeb December 09, 2020)Read the full story at https://www.prweb.com/releases/catalent_appoints_nakaya_matsumaru_as_general_manager_of_its_new_clinical_supply_facility_in_shiga_japan/prweb17601638.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 9, 2020 Category: Pharmaceuticals Source Type: news

OHSU study finds no adverse health effects in monkeys from gene therapy technique
Shoukhrat Mitalipov led the research, which has followed a group of macaques for more than a decade. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 8, 2020 Category: Pharmaceuticals Authors: Elizabeth Hayes Source Type: news

Novel Gene Therapy Wows for BCG-Unresponsive Bladder Cancer Novel Gene Therapy Wows for BCG-Unresponsive Bladder Cancer
A novel gene therapy for BCG-unresponsive NMIBC, nadofaragene firadenovec, is being suggested as a"new gold standard" for these patients.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 8, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Could Gene Therapy Cure Sickle Cell Disease? Two New Studies Raise Hopes
Title: Could Gene Therapy Cure Sickle Cell Disease? Two New Studies Raise HopesCategory: Health NewsCreated: 12/5/2020 12:00:00 AMLast Editorial Review: 12/7/2020 12:00:00 AM (Source: MedicineNet Chronic Pain General)
Source: MedicineNet Chronic Pain General - December 7, 2020 Category: Anesthesiology Source Type: news

Bayer-Atara-Biotherapeutics-enter-strategic-collaboration-generation-mesothelin-targeted-CAR-T
Agreement is fundamental element of Bayer’s new Cell & Gene Therapy strategy / Bayer to enter CAR-T cell therapy space and expand oncology development pipeline with groundbreaking technology / Recognizes the leading position of Atara’s technology platform in allogeneic cell therapy / Partnership will focus on the next generation, off-the-shelf T-cell immunotherapy ATA3271 for treatment of high mesothelin-expressing tumors / Atara to receive upfront payment of USD 60 million, and up to a total of USD 610 million for development, regulatory and commercialization milestones, plus tiered royalties up to low dou...
Source: Bayer Company News - December 7, 2020 Category: Pharmaceuticals Source Type: news

Could Gene Therapy Cure Sickle Cell Disease? Two New Studies Raise Hopes
SATURDAY, Dec. 5, 2020 -- A pair of new gene therapies promise a potentially lasting cure for sickle cell disease by subtly altering the genetic information in patients'bone marrow cells, researchers report. Both therapies work by switching on a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 5, 2020 Category: General Medicine Source Type: news

NIH researchers link cases of ALS and FTD to a mutation associated with Huntington ’s disease
Previously unknown genetic connection could be a target for gene therapy. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - December 4, 2020 Category: American Health Source Type: news

Mimicking the effect of exercise with gene therapy
(Norwegian University of Science and Technology) Gene therapy is the most effective method to be able to provide health benefits you normally gain through physical exercise. This means of " training " could be helpful for folks who can't exercise in the usual ways. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 4, 2020 Category: International Medicine & Public Health Source Type: news

UCLA receives $7.3 million grant to build state-of-the-art facility for developing gene, cell therapies
UCLA has received a $7.3 million grant from the National Institutes of Health to build a state-of-the-art facility in which to produce gene and cell therapies aimed at treating a host of illnesses and conditions.The new 13,000-square-foot facility, to be constructed in UCLA ’s Center for the Health Sciences, will provide a highly regulated environment with features such as systems to manage air flow and filtering, laboratory spaces and bioreactors. The new facility is expected to be ready for use in 2023.“This grant provides critical funds to build a facility that will enable the development of a new generation...
Source: UCLA Newsroom: Health Sciences - December 4, 2020 Category: Universities & Medical Training Source Type: news

Gene therapy for CLN2 disease
(Source: ScienceNOW)
Source: ScienceNOW - December 3, 2020 Category: Science Authors: Norton, M. Tags: twis Source Type: news

Janssen Acquires Rights to Novel Gene Therapy, Pioneering Treatment Solutions for Late-Stage Age-Related Macular Degeneration
RARITAN, NJ, December 2, 2020 – Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, today announced the acquisition of rights to Hemera Biosciences, LLC’s investigational gene therapy HMR59, administered as a one-time, outpatient, intravitreal injection to help preserve vision in patients with geographic atrophy, a late-stage and severe form of age-related macular degeneration (AMD). Financial terms of the transaction with Hemera Biosciences, a privately-owned biotechnology company, are not being disclosed. Patients with AMD often have low levels of CD59, a prote...
Source: Johnson and Johnson - December 2, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

The New Coronavirus Vaccine Is Changing The Future Of Medicine
The success of mRNA vaccines could usher in a new era of medical science — not just for vaccines, but for cancer treatments, gene therapy, and more. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - December 2, 2020 Category: Pharmaceuticals Authors: Caroline Seydel, Contributor Tags: Healthcare /healthcare Innovation /innovation Editors' Pick editors-pick Coronavirus Source Type: news

RoosterBio Collaborates with Sartorius to Expand Cell and Gene Therapy...
The partnership launches RoosterBio’s first international platform with off-the-shelf working cell banks and hMSC bioprocess media products in Asia(PRWeb December 02, 2020)Read the full story at https://www.prweb.com/releases/roosterbio_collaborates_with_sartorius_to_expand_cell_and_gene_therapy_manufacturing_platform_technology_into_south_korea/prweb17574339.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 2, 2020 Category: Pharmaceuticals Source Type: news

A new spin-off company to develop the first treatment against pulmonary fibrosis based on telomerase
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) Maria Blasco from the Spanish National Cancer Research Centre (CNIO, Madrid) and F à tima Bosch from the Universitat Aut ò noma de Barcelona (UAB, Barcelona) have founded the new 'Telomere Therapeutics', with an investment from 'Invivo Ventures'. The researchers will develop a new telomerase gene therapy to treat this age-related disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 1, 2020 Category: International Medicine & Public Health Source Type: news